Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING
GLOBETECH PUBLISHING
JIB

Transatlantic Partners to Produce Pyrogen-Free Containers for the Biopharmaceutical Industry

By BiotechDaily International staff writers
Posted on 30 Sep 2013
Image: Triple-vacuum-packed Pyrofree vials (Photo courtesy of ATMI, Inc.).
Image: Triple-vacuum-packed Pyrofree vials (Photo courtesy of ATMI, Inc.).
Image: Cross section view of triple-packed Pyrofree vials vials (Photo courtesy of ATMI, Inc.).
Image: Cross section view of triple-packed Pyrofree vials vials (Photo courtesy of ATMI, Inc.).
American and French manufacturers of products for the biopharmaceutical industry are teaming up to produce a line of sterile, pyrogen-free vials and containers.

A pyrogen is defined as any substance that can cause a fever. Bacterial pyrogens include endotoxins, which are poisonous substances inside the bacterial cell that are released only after destruction of the cell wall. This can happen during pharmaceutical sterilization processes that use harsh conditions such as gamma-irradiation, exposure to ethylene oxide gas, and steam sterilization.

Endotoxins can become pyrogenic when released into the bloodstream or other tissue where they are not usually found. Thus, it is critical to ensure there are no pyrogens present on the primary packaging of injectable drugs. The injection of endotoxins into the blood can cause severe hazard to a patient and in some cases, lead to septic shock.

Depyrogenation, or the removal of pyrogens, is required in the aseptic filling process of parenteral drugs. To guarantee the highest level of depyrogenated plasticware for biopharmaceutical manufacturing, ATMI, Inc. (Danbury, CT, USA), a global technology company and leader in single-use bioprocess solutions, is introducing a line of pyrogen-free vials (Pyrofree) in collaboration with the contract-manufacturing company Disposable-Lab (Martillac, France).

Pyrofree vials are made to withstand high temperatures during depyrogenation and sterilization. After these steps, the vials are double vacuum packed in a PEEK (polyether ether ketone) bag for tamper-evidence, as well as to maintain sterility and guarantee no external contact. A third film layer is added to the packaging under vacuum in a Class C cleanroom to protect the vials from any breakage during transportation and eliminate the need for a support tray.

"We have come together with Disposable-Lab to offer this comprehensive solution in support of our customers' end goal of advancing patient health and safety," said Mario Philips, general manager of ATMI. "Pyrofree vials can be incorporated into ATMI's existing ultra-clean sterile packaging and fill/finish technologies, or used independently."

"Pyrofree brings several clear benefits including the most cost-effective solution on the market, scalability from small to commercial-scale batches, and availability in both molded and tubular formats," said Jean-Pascal Zambaux, majority owner of Disposable-Lab. "The vials may also be used for commercial safety stocks of injectables, and feature sizes up to one liter."

Related Links:
ATMI, Inc.
Disposable-Lab


comments powered by Disqus

Channels

Genomics/Proteomics

view channel
Image: Illustration of the apoER2 receptor protein shows the structure of the entire protein in detail (Photo courtesy of Wikimedia Commons).

Risk of Cardiovascular Disease Linked to Apolipoprotein E Variants

The apoE4 variant form of circulating apolipoprotein E (apoE) leads to increased risk of cardiovascular disease by blocking binding of the normal apoE3 form to the apoliprotein E receptor 2 (apoER2) in... Read more

Drug Discovery

view channel
Image: S-649266 has more robust antibacterial activity than established antibiotics against multidrug-resistant bacteria (Photo courtesy of Shionogi).

Novel Antibiotic Shows Potential for Broad Range of Infections

The emergence of bacterial resistance to known antibacterial agents is becoming a major challenge in treating the infection caused by multi drug resistant (MDR) bacteria. In order to treat bacterial... Read more

Business

view channel

Collaboration of Mayo Clinic and IBM Cognitive Computer Devised to Improve Clinical Trial Research

The Mayo Clinic (Rochester, MN, USA) and IBM (Armonk, NY, USA) recently announced plans to pilot Watson, the IBM cognitive computer, to match patients more rapidly with suitable clinical trials. A proof-of-concept phase is currently ongoing, with the intent to introduce it into clinical use in early 2015.... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.